Free Trial

Surmodics 11/6/2024 Earnings Report

Surmodics logo
$39.96 -0.05 (-0.12%)
(As of 12/17/2024 05:27 PM ET)

Surmodics EPS Results

Actual EPS
-$0.13
Consensus EPS
-$0.27
Beat/Miss
Beat by +$0.14
One Year Ago EPS
N/A

Surmodics Revenue Results

Actual Revenue
$33.23 million
Expected Revenue
$30.69 million
Beat/Miss
Beat by +$2.54 million
YoY Revenue Growth
N/A

Surmodics Announcement Details

Quarter
Time
Before Market Opens

Conference Call Resources

Musk threatens Liberal’s fake “energy crisis” (Ad)

Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.

To get the full details on the fake “energy crisis” of America, watch this now

Surmodics Earnings Headlines

Surmodics (NASDAQ:SRDX) Earns Hold Rating from Analysts at StockNews.com
A conspiracy Trump won’t unseal
New documentary reveals the lost wealth-building secret hidden deep within ancient religious texts from almost every civilization… an investment one expert says is “so perfect that only God could have created it.” Watch it now to discover how this asset that you’ve likely never considered before can produce returns so safe, secure, and endless it is nothing short of miraculous.
Surmodics Inc. Reports Q4 and FY 2024 Results
Hold Rating Maintained for SurModics Amid Acquisition Uncertainty
See More Surmodics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Surmodics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Surmodics and other key companies, straight to your email.

About Surmodics

Surmodics (NASDAQ:SRDX), together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

View Surmodics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings